-
Views
-
Cite
Cite
James V. Hennessey, Generic vs Name Brand L-Thyroxine Products: Interchangeable or Still Not?, The Journal of Clinical Endocrinology & Metabolism, Volume 98, Issue 2, 1 February 2013, Pages 511–514, https://doi.org/10.1210/jc.2012-4310
Close - Share Icon Share
Extract
This issue of the JCEM provides us with new clinical data on L-thyroxine (LT4) equivalence (1, 2). The studies seem to reach opposite conclusions, but an understanding of the regulatory history shows us that they assess different aspects of the question. Before T4 was comprehensively regulated by the Food and Drug Administration (FDA), Hansen (3) asserted that the 2 leading name brand preparations of LT4 were equivalent. Within 5 years, no less than 10 studies assessed the “bioequivalence” of these 2 products using various methods and concluded that they either were or were not equivalent (4). In 1997, due to concerns with product potency and variability, the FDA declared LT4 preparations to be “new” drugs and required that all existing and future LT4 products be approved through the new drug application (NDA) process in order to remain on the US market (5, 6). This established uniform expectations for drug performance and resulted in a significant improvement in the LT4 products available for clinical use (7). The NDA products were unique formulations and were not considered interchangeable. This remained the case until the abbreviated NDA process of measuring relative bioavailability (bioequivalence) of LT4 products was implemented to provide a mechanism for assessing the potential interchangeability of generic and referenced name brand LT4 preparations (8). Shortcomings of the traditional pharmacokinetic method (9) resulted in a modification of the process to correct for endogenous T4 (10), but concerns remained that potentially clinically significant differences in a LT4 dose of 12.5% or more might not be recognized with the pharmacokinetic approach (9) in products designated as bioequivalent by the pharmacokinetic standard (11). Therapeutic equivalence codes were assigned once products met the bioequivalence specifications. The designation of AB was assigned if the standard for bioequivalence (8) was met, or products were rated as BX (not interchangeable) if this standard was not met (8). Current therapeutic equivalence ratings are summarized in Table 1 (12).
